Baseline characteristics of patients followed long-term after bone marrow transplantation from donors with allergic disease
. | . | . | . | Pre-BMT spirometry . | . | . | ||
|---|---|---|---|---|---|---|---|---|
| Patient no.* . | Age at BMT, y (sex) . | Follow-up period, y . | Diagnosis† . | FEV1, L (%) . | FVC, L (%) . | FEV1/FVC . | ||
| 1 | 14 (M) | 15.7 | ALL-rem | 3.87 (104) | 4.20 (104) | 0.92 | ||
| 2 | 43 (M) | 16.3 | CML-CP | 3.49 (95) | 4.43 (98) | 0.79 | ||
| 3 | 38 (F) | 15.8 | CML-CP | 2.81 (102) | 3.92 (102) | 0.72 | ||
| 6 | 17 (F) | 15.0 | AML-rem | 2.86 (99) | 3.43 (103) | 0.83 | ||
| 11 | 47 (M) | 14.4 | CML-CP | 4.23 (113) | 5.41 (116) | 0.78 | ||
. | . | . | . | Pre-BMT spirometry . | . | . | ||
|---|---|---|---|---|---|---|---|---|
| Patient no.* . | Age at BMT, y (sex) . | Follow-up period, y . | Diagnosis† . | FEV1, L (%) . | FVC, L (%) . | FEV1/FVC . | ||
| 1 | 14 (M) | 15.7 | ALL-rem | 3.87 (104) | 4.20 (104) | 0.92 | ||
| 2 | 43 (M) | 16.3 | CML-CP | 3.49 (95) | 4.43 (98) | 0.79 | ||
| 3 | 38 (F) | 15.8 | CML-CP | 2.81 (102) | 3.92 (102) | 0.72 | ||
| 6 | 17 (F) | 15.0 | AML-rem | 2.86 (99) | 3.43 (103) | 0.83 | ||
| 11 | 47 (M) | 14.4 | CML-CP | 4.23 (113) | 5.41 (116) | 0.78 | ||
FEV1 denotes the forced expiratory volume in one second; FVC, forced vital capacity; ALL, acute lymphoblastic leukemia; rem, remission; CML chronic myelogenous leukemia; CP, chronic phase; and AML, acute myelogenous leukemia.
Patient number is based on designation in the original cohort.1
Diagnosis and marrow status at the time of transplantation.